Surface Protein Treatment Pipeline Review H2 2016

PUNE, INDIA, October 5, 2016 /EINPresswire.com/ -- ‘Surface Protein gp120 - Pipeline Review, H2 2016’, provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Complete Report @ https://www.wiseguyreports.com/reports/668892-surface-protein-gp120-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120
- The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects
- The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Get Sample Report @ https://www.wiseguyreports.com/sample-request/668892-surface-protein-gp120-pipeline-review-h2-2016

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Surface Protein gp120
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have any query @ https://www.wiseguyreports.com/enquiry/668892-surface-protein-gp120-pipeline-review-h2-2016

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Surface Protein gp120 Overview 8
Therapeutics Development 9
Surface Protein gp120 - Products under Development by Stage of Development 9
Surface Protein gp120 - Products under Development by Therapy Area 10
Surface Protein gp120 - Products under Development by Indication 11
Surface Protein gp120 - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Surface Protein gp120 - Products under Development by Companies 14
Surface Protein gp120 - Products under Development by Universities/Institutes 16
Surface Protein gp120 - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Surface Protein gp120 - Companies Involved in Therapeutics Development 24
GlaxoSmithKline Plc 24
Osel, Inc. 25
Sanofi Pasteur SA 26
TeneoBio Inc 27
United Biomedical, Inc. 28
ViiV Healthcare Limited 29
Surface Protein gp120 - Drug Profiles 30
Abzentek - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AIDSVAX B/B + ALVAC-HIV vCP1521 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Biologic for Infectious Disease - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BMD-101 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BMD-104 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BMS-585248 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DS-003 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
fostemsavir tromethamine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
HIV [strains C1086 + TV1] (bivalent) vaccine - Drug Profile 42
Continued…

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=668892

Follow Us:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.